Join the Oncology Voice Network. Join for Free
Finding MSL Success in Cross Therapeutic Transitions
medical science liaison therapeutic area transition key opinion leaders leveraging transferable skills building professional relationships

Finding MSL Success in Cross Therapeutic Transitions


Share This Article


Summary

In this episode, Tom Caravela welcomes Mitch D'Rosario and Deanna Tucker to discuss the intricacies of switching therapeutic areas as a Medical Science Liaison (MSL). They share personal experiences and address common concerns when transitioning into new therapeutic spaces. The conversation delves into strategies for gaining expertise, accessing Key Opinion Leaders (KOLs), and overcoming challenges unique to different therapeutic areas. The guests emphasize the importance of leveraging transferable skills and relationship equity to establish credibility. They also touch on the impact of AI on MSL job applications and offer insights on adding value to KOLs. The episode concludes with reflections on building strong professional relationships.

Key Points

  • Transitioning between therapeutic areas can be daunting, but leveraging core MSL skills, such as pre-call planning and building relationships, is crucial for success.
  • Humility and a willingness to learn are essential when switching therapeutic areas, as they help build credibility with new KOLs and adapt to new scientific landscapes.
  • Leveraging your network and showcasing your transferable skills and experience can significantly aid in making a successful therapeutic area transition.

Click for Source
medical science liaison, therapeutic area transition, key opinion leaders, leveraging transferable skills, building professional relationships

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN